JP2016514727A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514727A5
JP2016514727A5 JP2016504377A JP2016504377A JP2016514727A5 JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5 JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP6360881B2 (ja
JP2016514727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031442 external-priority patent/WO2014153509A1/en
Publication of JP2016514727A publication Critical patent/JP2016514727A/ja
Publication of JP2016514727A5 publication Critical patent/JP2016514727A5/ja
Application granted granted Critical
Publication of JP6360881B2 publication Critical patent/JP6360881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016504377A 2013-03-22 2014-03-21 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ Active JP6360881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804314P 2013-03-22 2013-03-22
US61/804,314 2013-03-22
PCT/US2014/031442 WO2014153509A1 (en) 2013-03-22 2014-03-21 Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase

Publications (3)

Publication Number Publication Date
JP2016514727A JP2016514727A (ja) 2016-05-23
JP2016514727A5 true JP2016514727A5 (OSRAM) 2017-04-27
JP6360881B2 JP6360881B2 (ja) 2018-07-18

Family

ID=51581522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504377A Active JP6360881B2 (ja) 2013-03-22 2014-03-21 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ

Country Status (6)

Country Link
US (2) US9724354B2 (OSRAM)
EP (1) EP2976086B1 (OSRAM)
JP (1) JP6360881B2 (OSRAM)
CN (1) CN105209042B (OSRAM)
CA (1) CA2907726A1 (OSRAM)
WO (1) WO2014153509A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
ITUA20164278A1 (it) * 2016-06-10 2017-12-10 International Soc For Drug Development S R L COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
EP4243816A4 (en) * 2020-11-13 2024-11-27 Neuron23, Inc. KINASE MODULATORS AND METHODS OF USE THEREOF
CN112782402A (zh) * 2020-12-11 2021-05-11 南京市儿童医院 一种利用mk-5108阻断aurka来减轻肾纤维化的方法

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU711592B2 (en) 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP4205168B2 (ja) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
JP3784076B2 (ja) 1997-02-07 2006-06-07 プリンストン ユニヴァーシティ 変性ヌクレオチド三燐酸基質を利用できる組み換えタンパクキナーゼ
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1155599C (zh) 1997-09-29 2004-06-30 明治制果株式会社 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
US6251689B1 (en) 1998-05-14 2001-06-26 Telik, Inc. Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
ATE248834T1 (de) 1998-11-16 2003-09-15 Basf Ag Herbizide 3-(benzo(ox/thi)azol-7-yl)-1h-pyrimidin-2,4-dio e
DE1140938T1 (de) 1999-01-11 2003-01-09 Princeton University, Princeton Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2001010462A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PT1212327E (pt) 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
EP1315484A1 (en) 2000-03-24 2003-06-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
WO2003082341A1 (en) 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
AU2005213472A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005085248A1 (en) 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ES2299080T3 (es) 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
BRPI0609988A2 (pt) 2005-04-22 2010-05-18 Wyeth Corp derivados de diidrobenzofurano e usos dos mesmos
CA2620106A1 (en) 2005-08-25 2007-03-01 F. Hoffman-La Roche Ag P38 map kinase inhibitors and methods for using the same
KR101011957B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
BRPI0616459A2 (pt) 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
TW201307354A (zh) 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
HUE067285T2 (hu) 2006-03-24 2024-10-28 Bioverativ Therapeutics Inc PC5 mint IX-es faktor propeptidet feldolgozó enzim
EA200870385A1 (ru) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
KR20130087054A (ko) 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
MX2009000132A (es) 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
DK2046292T3 (da) 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP1900729A1 (en) 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
BRPI0718100A2 (pt) 2006-10-31 2013-11-05 Achillion Pharmaceuticals Inc Composições farmacêuticas de elvucitabina
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
WO2009021990A1 (en) 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
CA2716334A1 (en) 2007-11-13 2009-05-22 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
KR20160130519A (ko) 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CA2764983A1 (en) 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
EP2470546B1 (en) 2009-08-28 2013-07-24 Takeda Pharmaceutical Company Limited Hexahydrooxazinopteridine compounds for use as mtor inhibitors
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120010230A1 (en) 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
JP6047149B2 (ja) 2011-05-04 2016-12-21 インテリカイン， エルエルシー 併用の医薬組成物およびその使用

Similar Documents

Publication Publication Date Title
JP2016514727A5 (OSRAM)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2014503574A5 (OSRAM)
JP2015500884A5 (OSRAM)
JP2015532295A5 (OSRAM)
JP2015511638A5 (OSRAM)
JP2015520143A5 (OSRAM)
JP2019500352A5 (OSRAM)
JP2020514311A5 (OSRAM)
JP2017524702A5 (OSRAM)
JP2014500295A5 (OSRAM)
JP2014513138A5 (OSRAM)
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
JP2012513390A5 (OSRAM)
JP2016518437A5 (OSRAM)
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
RU2015124002A (ru) Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
JP2008535902A5 (OSRAM)
JP2017527532A5 (OSRAM)
JP2012520861A5 (OSRAM)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2016513696A5 (OSRAM)
JP2017510610A5 (OSRAM)
JP2016515628A5 (OSRAM)